Quality assessment of clinical practice guidelines on the treatment of hepatocellular carcinoma or metastatic liver cancer

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Wang, Yingqiang ^a,b   Luo, Qianqian ^a   Li, Youping ^a   Wang, Haiqing ^c   Deng, Shaolin ^a   Wei, Shiyou ^a   Li, Xianglian ^a  

^a SICHUAN UNIVERSITY   (China)

^b Aviation Industry of China   (China)

^c YICHUN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HORMONE; SORAFENIB; YTTRIUM 90;

ADVANCED CANCER; ARTICLE; BRACHYTHERAPY; CHEMOEMBOLIZATION; CLINICAL PROTOCOL; CONFLICT OF INTEREST; CONSENSUS DEVELOPMENT; EVIDENCE BASED MEDICINE; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; METASTATIC LIVER CANCER; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; QUALITY CONTROL; SYSTEMATIC REVIEW; CARCINOMA, HEPATOCELLULAR; HEALTH CARE QUALITY; LIVER NEOPLASMS; NEOPLASM METASTASIS; PROCEDURES; STATISTICS AND NUMERICAL DATA;

CARCINOMA, HEPATOCELLULAR; EVIDENCE-BASED MEDICINE; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; PRACTICE GUIDELINES AS TOPIC; QUALITY ASSURANCE, HEALTH CARE;

EID: 84905668720     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103939     Document Type: Article

References (64)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) GLOBOCAN 2008 v2.0,Cancer Incidence and Mortality Worldwise:IARC cancerBase No. 10[Internet]. http://globocan.iarc.fr. Accessed November 24, 2012.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cance;127(12):2893- 2917.
3. Lang K, Danchenko N, Gondek K, Shah S, Thompson D (2009) The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 50(1):89-99.
4. White LA, Menzin J, Korn JR, Friedman M, Lang K, et al. (2012) Medical care costs and survival associated with hepatocellular carcinoma among the elderly. Clin Gastroenterol Hepatol 10(5):547-554.
5. Field MJ, Lohr KN, eds. (1990) Clinical Practice Guidelines:directions for a new program. Washington,D.C.: Institute of Medicine.National Academy Press.
6. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J (1999) Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ 318(7182):527-530. (Pubitemid 29189000)
7. Burls A.(2010) AGREE II-improving the quality of clinical care. Lancet 376(9747):1128-1129.
8. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, et al. (2010) AGREE II: advancing guideline development, reporting, and evaluation in health care. Prev Med 51(5):421-424.
9. AGREE Next Steps Consortium (2009) The AGREE II Intrument [Electronic version]. http://www.agreetrust.org.
10. Schmidt S, Follmann M, Malek N, Manns MP, Greten TF (2011) Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 26(12):1779-1786.
11. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097.
12. Field AP (2005) Kendall's Coefficient of Concordance. Encyclopedia of Statistics in Behavioral Science: John Wiley & Sons, Ltd.
13. Devlin J, O'Grady J (1999) Indications for referral and assessment in adultliver transplantation: a clinical guideline. Gut 45:1-22.
14. Ryder SD (2003) Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 52 Suppl 3:iii1-8.
15. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208-1236. (Pubitemid 43112690)
16. Murray KF, Carithers RL (2005) AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 41(6):1407-1432. (Pubitemid 40770295)
17. O'Grady J, Taylor C, Brook G (2005) Guidelines for liver transplantation in patients with HIV infection(2005). HIV Med 6:149-153. (Pubitemid 41038590)
18. Parikh P, Malhotra H, Jelic S (2008) Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 Suppl 2:ii27-28.
19. Knox J, Cosby R, Chan K, Sherman M (2008) Sorafenib for Advanced Hepatocellular Carcinoma. Toronto: Cancer Care Ontario (CCO).
20. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S,et al. (2008) Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 38(1):37-51. (Pubitemid 350182575)
21. Poon D, Anderson BO, Chen LT, Tanaka K,Lau WY, et al. (2009) Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10(11):1111-1118.
22. Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, et al. (2009) NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 7(4):350-391.
23. Jelic S, Sotiropoulos GC (2010) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 Suppl 5:v59-64.
24. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, et al. (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4(2):439-474.
25. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020-1022.
26. National Institute for Health and Clinical Excellence (2012) NICE technology appraisal guidance 189: Sorafenib for the treatment of advanced hepatocellular carcinoma. London.
27. Peck-Radosavljevic M, Sieghart W, Kolblinger C, Reiter M, Schindl M, et al. (2012) Austrian Joint OGGH-OGIR-OGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. Wiener Klinische Wochenschrift 124(3-4):104-110.
28. Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, Galle PR, et al. (2012) EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 56(4):908-943.
29. Abdo AA, Hassanainh M, AlJumah A, Al Olayan A, Sanai FM, et al. (2012) Saudi Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Technical Review and Practice Guidelines. Ann Saudi Med 32(2):174-199.
30. Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, et al. (2006) Guidelines for resection of colorectal cancer liver metastases. Gut 55 Suppl 3:iii1-8. (Pubitemid 44085662)
31. Bipat S, van Leeuwen MS, Ijzermans JN, Comans EF, Planting AS, et al. (2007) Evidence-based guideline on management of colorectal liver metastases in the Netherlands. Neth J Med 65(1):5-14. (Pubitemid 46152289)
32. Xu J, Qin X, Wang J, Zhang S, Zhong Y, et al. (2011) Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. J Cancer Res Clin Oncol 137(9):1379-1396.
33. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421-430. (Pubitemid 32844200)
34. Van Vlierberghe H, Borbath I, Delwaide J, Henrion J, Michielsen P, et al. (2004) BASL guidelines for the surveillance, diagnosis and treatment of hepatocellular carcinoma. Acta Gastroenterol Belg 67(1):14-25. (Pubitemid 38552573)
35. Kudo M, Okanoue T (2007) Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 72:2-15. (Pubitemid 350256660)
36. Ye SL (2009) [Expert consensus on standardization of the management of primary liver cancer][Article in Chinese]. Zhonghua Gan Zang Bing Za Zhi 17(6):403-410.
37. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, et al. (2010) Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 40(7):667-685.
38. Kaneko S, Furuse J, Kudo M, Ikeda K, Honda M, et al. (2012) Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update. Hepatol Res 42(6):523-542.
39. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, et al. (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68(1):13-23. (Pubitemid 46589861)
40. Steinmuller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, et al. (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87(1):47-62. (Pubitemid 350308294)
41. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, et al. (2012) ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary. Neuroendocrinology 95(2):157-176.
42. Chinese Medical Association of Gastrointestinal and Colorectal Surgery Group, Chinese Anti-Cancer Association of Colorectal Cancer. (2010)Guidelines for the diagnosis and management of colorectal cancer Liver metastases (V2010) [Article in Chinese]. Chin J Gastrointest Surg 13(6):457-470.
43. Izumi N (2010) Diagnostic and treatment algorithm of the Japanese society of hepatology: a consensus-based practice guideline. Oncology 78 Suppl 1:78-86.
44. Kudo M (2010) Real practice of hepatocellular carcinoma in Japan: conclusions of the Japan Society of Hepatology 2009 Kobe Congress. Oncology 78 Suppl 1:180-188.
45. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, et al. (2011) Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig dis 29(3):339-364.
46. Abad A, Figueras J, Valls C, Carrato A, Pardo F, et al. (2007)mGuidelines for the detection and treatment of liver metastases of colorectal cancer. Clin transl oncol 9(11):723-730.
47. Abdalla EK, Bauer TW, Chun YS, D'Angelica M, Kooby DA, et al. (2013) Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements. HPB(Oxford) 15(2):119-130.
48. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, et al. (2010) World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. J gastrointestin liver dis 19(3):311-317.
49. Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, et al. (2011) EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 38(7):1393-1406.
50. Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, et al. (2011) Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver transpl 17 Suppl 2:S81-89.
51. Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N (2011) Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. Liver transpl 17 Suppl 2:S6-13.
52. Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, et al. (2013) Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB(Oxford) 15(2):106-115.
53. McAlister FA, van Diepen S, Padwal RS, Johnson JA, Majumdar SR (2007) How evidence-based are the recommendations in evidence-based guidelines? PLoS Med 4(8):e250.
54. Alonso-Coello P, Irfan A, Sola I, Gich I, Delgado-Noguera M, et al. (2010) The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies. Qual Saf Health Care 19(6):e58.
55. Grilli R, Magrini N, Penna A, Mura G, Liberati A (2000) Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet 355(9198):103-106. (Pubitemid 30068554)
56. Rosenfeld RM, Shiffman RN, Robertson P (2013) Clinical practice guideline development manual, third edition: a quality-driven approach for translating evidence into action. Otolaryngol Head Neck Surg 148(1 Suppl):S1-S55.
57. Zheng ZH, Cui SQ, Lu XQ, Zakus D, Liang WN, et al. (2012) Analysis of the status of Chinese clinical practice guidelines development. BMC Health Serv Res 12:218.
58. Chen YL, Yao L, Xiao XJ, Wang Q, Wang ZH, et al. (2012) Quality assessment of clinical guidelines in China: 1993-2010. Chin Med J (Engl) 125(20):3660-3664.
59. Cluzeau F, Wedzicha JA, Kelson M, Corn J, Kunz R, et al. (2012) Stakeholder Involvement: How to Do It Right: Article 9 in Integrating and Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report. Proc Am Thorac Soc 9(5):269-273.
60. Neuman J, Korenstein D, Ross JS, Keyhani S (2011) Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. BMJ 343:d5621.
61. Choudhry NK, Stelfox HT, Detsky AS (2002) Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 287(5):612-617. (Pubitemid 34252013)
62. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, et al. (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383-394.
63. Campbell EG (2010) Public disclosure of conflicts of interest: moving the policy debate forward. Arch Intern Med 170(8):667.
64. Scott IA, Guyatt GH (2011) Clinical practice guidelines: the need for greater transparency in formulating recommendations. Med J Aust195(1):29-33.